Skip to content

LEXARIA BIOSCIENCE CORP.: 10-Q filed 2023-07-14

What LEXARIA BIOSCIENCE CORP. reported in its quarterly report filed 2023-07-14 (fiscal Q3 2023): 29 published measures, 85 facts as tagged in accession 0001640334-23-001286.

This filing

Form
10-Q (quarterly report)
Filed
2023-07-14
Fiscal period
fiscal Q3 2023
Accession
0001640334-23-001286 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All LEXARIA BIOSCIENCE CORP. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-05-315,239,637USD
At 2022-08-317,833,927USD
At 2022-05-319,137,943USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-05-311,198,491USD
At 2022-08-31201,437USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-05-314,395,490USD
At 2022-08-317,948,904USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-03-01 to 2023-05-31-2,371,505USD92
2022-09-01 to 2023-05-31-5,425,580USD273
2022-12-01 to 2023-02-28-1,298,131USD90
2022-09-01 to 2022-11-30-1,755,944USD91
2022-03-01 to 2022-05-31-2,382,925USD92
2021-09-01 to 2022-05-31-5,801,859USD273
2021-12-01 to 2022-02-28-1,425,777USD90
2021-09-01 to 2021-11-30-1,993,157USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2022-09-01 to 2023-05-31-4,259,557USD273
2021-09-01 to 2022-05-31-3,702,724USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2022-09-01 to 2023-05-3133,748USD273
2021-09-01 to 2022-05-3149,188USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2023-03-01 to 2023-05-3193,150USD92
2022-09-01 to 2023-05-31229,641USD273
2022-03-01 to 2022-05-3199,717USD92
2021-09-01 to 2022-05-31144,247USD273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2022-09-01 to 2023-05-31229,641USD273
2021-09-01 to 2022-05-31144,247USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2022-09-01 to 2023-05-311,711,418USD273
2021-09-01 to 2022-05-31-33,395USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2022-09-01 to 2023-05-31-101,173USD273
2021-09-01 to 2022-05-31-130,595USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-05-31-44,524,108USD
At 2022-08-31-39,098,528USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-05-31276,898USD
At 2022-08-31315,505USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2022-09-01 to 2023-05-31160,748USD273
2021-09-01 to 2022-05-31519,718USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-05-314,235,490USD
At 2022-08-316,977,516USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-05-311,055,904USD
At 2022-08-31194,036USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2023-05-31172,284USD
At 2022-08-31201,784USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-03-01 to 2023-05-312,463,969USD92
2022-09-01 to 2023-05-315,661,651USD273
2022-03-01 to 2022-05-312,499,420USD92
2021-09-01 to 2022-05-315,984,147USD273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2023-05-310USD
At 2022-08-3138,418USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2023-03-01 to 2023-05-3180,403USD92
2022-09-01 to 2023-05-31198,141USD273
2022-03-01 to 2022-05-3181,082USD92
2021-09-01 to 2022-05-31113,655USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-03-01 to 2023-05-311,640,648USD92
2022-09-01 to 2023-05-313,166,315USD273
2022-03-01 to 2022-05-31752,095USD92
2021-09-01 to 2022-05-311,486,487USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-05-318,091,650shares
At 2022-08-315,950,998shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-05-313,163,906USD
At 2022-08-315,813,218USD
At 2022-05-317,051,083USD
At 2021-08-3110,917,797USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-05-3148,911,507USD
At 2022-08-3147,041,481USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2023-05-314,041,146USD
At 2023-02-284,631,848USD
At 2022-11-305,931,960USD
At 2022-08-317,632,490USD
At 2022-05-318,912,778USD
At 2022-02-2811,219,942USD
At 2021-11-3011,468,614USD
At 2021-08-3113,063,552USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2023-05-31452,413USD
At 2022-08-31379,993USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2023-03-01 to 2023-05-31-2,383,566USD92
2022-09-01 to 2023-05-31-5,463,510USD273
2022-03-01 to 2022-05-31-2,418,338USD92
2021-09-01 to 2022-05-31-5,870,492USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-03-01 to 2023-05-31823,321USD92
2022-09-01 to 2023-05-312,495,336USD273
2022-03-01 to 2022-05-311,747,325USD92
2021-09-01 to 2022-05-314,497,660USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2022-09-01 to 2023-05-3129,500USD273
2021-09-01 to 2022-05-31-90,574USD273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2022-09-01 to 2023-05-3143,069USD273
2021-09-01 to 2022-05-31-9,196USD273

Inspect the source

Entity
LEXARIA BIOSCIENCE CORP. / CIK 0001348362
Captured
2026-09-20T07:55:03.045Z
SEC response SHA-256
c8696dbfbdb8ee1a7522ea5b45a8c2d45cb12720b3d84857c1cda6bba2861389

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001348362.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))